139 related articles for article (PubMed ID: 36154762)
1. Germline BRCA mutation carriers are more likely to undergo cytoreductive surgery for relapsed, platinum sensitive, ovarian cancer.
Yfat K; Mariam K; Mario B; Hal H; Dana J; Lina S; Ilan B; Gregory P; Limor H
Gynecol Oncol; 2022 Nov; 167(2):256-260. PubMed ID: 36154762
[TBL] [Abstract][Full Text] [Related]
2. BRCA Mutation Status to Personalize Management of Recurrent Ovarian Cancer: A Multicenter Study.
Marchetti C; De Leo R; Musella A; D'Indinosante M; Capoluongo E; Minucci A; Benedetti Panici P; Scambia G; Fagotti A
Ann Surg Oncol; 2018 Nov; 25(12):3701-3708. PubMed ID: 30128899
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors value of germline and somatic brca in patients undergoing surgery for recurrent ovarian cancer with liver metastases.
Gallotta V; Conte C; D'Indinosante M; Capoluongo E; Minucci A; De Rose AM; Ardito F; Giuliante F; Di Giorgio A; Zannoni GF; Fagotti A; Margreiter C; Scambia G; Ferrandina G
Eur J Surg Oncol; 2019 Nov; 45(11):2096-2102. PubMed ID: 31227342
[TBL] [Abstract][Full Text] [Related]
4. Survival and Chemosensitivity in Advanced High Grade Serous Epithelial Ovarian Cancer Patients with and without a BRCA Germline Mutation: More Evidence for Shifting the Paradigm towards Complete Surgical Cytoreduction.
De Jong D; Otify M; Chen I; Jackson D; Jayasinghe K; Nugent D; Thangavelu A; Theophilou G; Laios A
Medicina (Kaunas); 2022 Nov; 58(11):. PubMed ID: 36363568
[TBL] [Abstract][Full Text] [Related]
5. Young Israeli women with epithelial ovarian cancer: prevalence of BRCA mutations and clinical correlates.
Helpman L; Zidan O; Friedman E; Kalfon S; Perri T; Ben-Baruch G; Korach J
J Gynecol Oncol; 2017 Sep; 28(5):e61. PubMed ID: 28657222
[TBL] [Abstract][Full Text] [Related]
6. The correlation between BRCA status and surgical cytoreduction in high-grade serous ovarian carcinoma.
Kim SR; Malcolmson J; Li X; Bernardini MQ; Hogen L; May T
Gynecol Oncol; 2021 Sep; 162(3):702-706. PubMed ID: 34256977
[TBL] [Abstract][Full Text] [Related]
7. Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.
Ledermann J; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott CL; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Dougherty B; Orr M; Hodgson D; Barrett JC; Matulonis U
Lancet Oncol; 2014 Jul; 15(8):852-61. PubMed ID: 24882434
[TBL] [Abstract][Full Text] [Related]
8. Impact of BRCA1/2 Mutations on the Efficacy of Secondary Cytoreductive Surgery.
Estati FL; Pirolli R; de Alencar VTL; Ribeiro ARG; Formiga MN; Torrezan GT; Carraro DM; Guimarães APG; Baiocchi G; da Costa AABA
Ann Surg Oncol; 2021 Jul; 28(7):3637-3645. PubMed ID: 33221980
[TBL] [Abstract][Full Text] [Related]
9. Germline and somatic mutations in homologous recombination genes among Chinese ovarian cancer patients detected using next-generation sequencing.
Zhao Q; Yang J; Li L; Cao D; Yu M; Shen K;
J Gynecol Oncol; 2017 Jul; 28(4):e39. PubMed ID: 28541631
[TBL] [Abstract][Full Text] [Related]
10. Outcomes of secondary cytoreductive surgery for patients with platinum-sensitive recurrent ovarian cancer.
Gockley A; Melamed A; Cronin A; Bookman MA; Burger RA; Cristae MC; Griggs JJ; Mantia-Smaldone G; Matulonis UA; Meyer LA; Niland J; O'Malley DM; Wright AA
Am J Obstet Gynecol; 2019 Dec; 221(6):625.e1-625.e14. PubMed ID: 31207237
[TBL] [Abstract][Full Text] [Related]
11. Association of BRCA1/2 mutations with prognosis and surgical cytoreduction outcomes in ovarian cancer patients: An updated meta-analysis.
Wang Y; Li N; Ren Y; Zhao J
J Obstet Gynaecol Res; 2022 Sep; 48(9):2270-2284. PubMed ID: 35698734
[TBL] [Abstract][Full Text] [Related]
12. BRCA mutation carriers suffering from ovarian cancer as a model for treatment decision in higher lines - Place for platinum reinduction.
Zikan M; Vecerova L; Dubova O; Sehnal B; Soukupova J
J Cancer Res Ther; 2023; 19(3):684-687. PubMed ID: 37470594
[TBL] [Abstract][Full Text] [Related]
13. Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer.
Paik ES; Heo EJ; Choi CH; Kim JH; Kim JW; Kim YM; Park SY; Lee JW; Kim JW; Kim BG
Cancer Sci; 2021 Dec; 112(12):5055-5067. PubMed ID: 34657357
[TBL] [Abstract][Full Text] [Related]
14. Current strategies for the targeted treatment of high-grade serous epithelial ovarian cancer and relevance of BRCA mutational status.
Gadducci A; Guarneri V; Peccatori FA; Ronzino G; Scandurra G; Zamagni C; Zola P; Salutari V
J Ovarian Res; 2019 Jan; 12(1):9. PubMed ID: 30691488
[TBL] [Abstract][Full Text] [Related]
15. BRCA1/2 mutations and expression: response to platinum chemotherapy in patients with advanced stage epithelial ovarian cancer.
Dann RB; DeLoia JA; Timms KM; Zorn KK; Potter J; Flake DD; Lanchbury JS; Krivak TC
Gynecol Oncol; 2012 Jun; 125(3):677-82. PubMed ID: 22406760
[TBL] [Abstract][Full Text] [Related]
16. Surgical cytoreduction for recurrent epithelial ovarian cancer.
Al Rawahi T; Lopes AD; Bristow RE; Bryant A; Elattar A; Chattopadhyay S; Galaal K
Cochrane Database Syst Rev; 2013 Feb; 2013(2):CD008765. PubMed ID: 23450588
[TBL] [Abstract][Full Text] [Related]
17. Outcomes of primary surgical cytoreduction in patients with BRCA-associated high-grade serous ovarian carcinoma.
Hyman DM; Long KC; Tanner EJ; Grisham RN; Arnold AG; Bhatia J; Phillips MF; Spriggs DR; Soslow RA; Kauff ND; Levine DA
Gynecol Oncol; 2012 Aug; 126(2):224-8. PubMed ID: 22579790
[TBL] [Abstract][Full Text] [Related]
18. The effect of germ-line BRCA mutations on response to chemotherapy and outcome of recurrent ovarian cancer.
Safra T; Rogowski O; Muggia FM
Int J Gynecol Cancer; 2014 Mar; 24(3):488-95. PubMed ID: 24457564
[TBL] [Abstract][Full Text] [Related]
19. BRCA testing, treatment patterns and survival in platinum-sensitive recurrent ovarian cancer - an observational cohort study.
Unni SK; Schauerhamer MB; Deka R; Tyczynski JE; Fernandes AW; Stevens V; Brixner DI; Stenehjem DD
J Ovarian Res; 2016 Mar; 9():18. PubMed ID: 27004793
[TBL] [Abstract][Full Text] [Related]
20. Olaparib maintenance monotherapy in platinum-sensitive, relapsed ovarian cancer without germline
Poveda AM; Davidson R; Blakeley C; Milner A
Future Oncol; 2019 Nov; 15(32):3651-3663. PubMed ID: 31553234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]